BRIBF Stock BRII BIOSCIENCE (BRIBF, $0.24) was a top winner yesterday, jumping +4.07%
at Tickeron.com
Loading...
BRIBF's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for BRIBF moved out of oversold territory on July 29, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 4 similar instances when the indicator left oversold territory. In of the 4 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on August 15, 2025. You may want to consider a long position or call options on BRIBF as a result. In of 19 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BRIBF just turned positive on August 13, 2025. Looking at past instances where BRIBF's MACD turned positive, the stock continued to rise in of 14 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
BRIBF moved below its 50-day moving average on July 25, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BRIBF crossed bearishly below the 50-day moving average on July 25, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BRIBF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.498) is normal, around the industry mean (19.660). P/E Ratio (0.000) is within average values for comparable stocks, (54.828). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.654). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (303.787).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRIBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology